Dear @availlant,
What are your thoughts about this drug? Does this drug target HBSag efficiently. HuaHui company and my country have signed a deal. Officials agreed to fast-track Phase III trials to deliver the treatment to eligible patients quickly under strict monitoring in our country.
Dear @Nawab ,
None of the HBsAg targeting antibodies either approved in China or in development in the EU work against HDV by targeting surface antigen. Like all foreign antibodies, they stimulate immunoreactivity, which in the case of HDV, acts to suppress the replication of HDV. Clinical trials have already shown these antibodies actually only achieve mild declines in HBsAg (likely from inactivation of cccDNA) and likely have little to no effect on subviral particles.
These antibody-based drugs will be life long treatments for HDV but have no future as HBV therapeutics.
Dear @availlant,
Could you please tell me when and where Replicor Phase IIa trial will be conducted if you have any idea? Will there be Phase IIb after Phase IIa?